Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife

REPLIGEN CORP

Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.
GAAP operating income flat at $14M; GAAP EPS $0.09 (down from $0.26).
Full year 2026 guidance raised: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09.
Announced definitive agreement to acquire BioLife Solutions, strengthening cell therapy position.
Cash and marketable securities $810M at June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.